T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the […]
We are honored to announce that Dr. Tse-Wen Chang, Chairman of T-E Pharma, and Dr. Hsin-Mao Chu, CEO of the
Great news! The long-acting GLP-1 receptor agonist TE-8105 has achieved an innovative breakthrough in formulation development, successfully creating a more
“The development of TE-6168, the novel thrombolytic fusion protein” was selected as a significant case of the Center for Drug
T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future
Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard
Great news! Our latest publication presents TE-1146 as a novel therapeutic strategy for the treatment of multiple myeloma. We are
